LGVN היקף נכסי החברה Longeveron Corporation
Longeveron Inc. (LGVN) specializes in the development of Lomecel-B, leveraging test results for heart hypoplasia and Alzheimer's disease. Its operations are protected by US laws, which eliminates geopolitical risks. The historical price action of total assets, reaching 16.12, is illustrated below. The team consists of elite biologists retained through generous stock options and grants to combat age-related pathologies.
פילוחי מדדים פיננסיים ומדדי שוק עבור Longeveron Corp (LGVN)
Institutional capital assesses the attractiveness of Longeveron Inc. (LGVN) based on the volume of resources required to complete clinical trials, as the success of cell therapy depends on treatment efficacy rather than market cycles. The dynamics of the company's total resources, calculated inversely via ROA, allow for the identification of accounting anomalies and an assessment of the asset's real material base to mitigate delisting risks.